Satralizumab

Phase 3Recruiting

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

NMDAR Autoimmune Encephalitis

Conditions

NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis

Trial Timeline

Sep 27, 2022 → Dec 14, 2029

NCT ID

NCT05503264

About Satralizumab

Satralizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for NMDAR Autoimmune Encephalitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05503264. Target conditions include NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05503264	Phase 3	Recruiting	Sep 27, 2022	Dec 14, 2029	NMDAR Autoimmune Encephalitis
NCT05271409	Phase 3	Recruiting	Aug 30, 2022	Dec 31, 2028	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
NCT04963270	Phase 3	Terminated	Oct 19, 2021	Sep 2, 2024	Generalized Myasthenia Gravis

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved

Pegasys® + Pegasys®Approved

ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3

R744 + Epoetin betaPhase 3

EmicizumabPhase 3